|1.||Griffin, J H: 3 articles (01/2014 - 07/2000)|
|2.||Bouchard, Beth A: 2 articles (10/2015 - 06/2015)|
|3.||Cramer, Thomas J: 2 articles (01/2014 - 06/2011)|
|4.||Gale, A J: 2 articles (01/2014 - 07/2000)|
|5.||Gale, Andrew J: 2 articles (01/2014 - 06/2011)|
|6.||Griffin, John H: 2 articles (01/2014 - 09/2002)|
|7.||Gertz, Jacqueline M: 1 article (10/2015)|
|8.||Key, Nigel S: 1 article (06/2015)|
|9.||Chapin, John: 1 article (06/2015)|
|10.||Tracy, Paula B: 1 article (06/2015)|
|1.||Hemophilia A (Haemophilia)
01/01/2014 - "Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant."
01/01/2014 - "To investigate the potential of engineered activated factor V (FVa) variants as bypassing agents in hemophilia A. "
09/01/2013 - "They play a major role in hemostasis by degrading the activated factor V and factor VIII. Deficiencies of protein C and protein S are associated with increased risk of thrombotic events. "
10/01/2015 - "Given the essential role of platelet-derived factor Va in clot formation, understanding the cellular and molecular mechanisms that regulate how platelets acquire this molecule will be important for the treatment of excessive bleeding or clotting."
11/01/1979 - "We report studies of a patient (M.S.) with a moderate to severe bleeding abnormality whose platelets are deficient in the platelet-surface component required for the factor Va-factor Xa binding. "
01/01/2014 - "An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C."
11/01/1979 - "Deficiency of factor Xa-factor Va binding sites on the platelets of a patient with a bleeding disorder."
02/01/2001 - "Studies were performed on a patient with a longstanding bleeding disorder whose major defects were impaired platelet prothrombinase activity in the absence of added factor Va, and a platelet factor V value that was either decreased or at the lower limit of normal when assayed on multiple occasions. "
|3.||Activated Protein C Resistance (APC Resistance)
06/01/1994 - "These results support the hypothesis that the APC resistance of some venous thrombophilic plasmas is caused by abnormal factor Va."
05/28/1994 - "Activated protein C resistance caused by Arg506Gln mutation in factor Va."
05/01/1997 - "The purpose of this study was to investigate the clinical use of a new chromogenic APC-resistance assay that is based on direct measurement of the effect of APC on factor Va cofactor activity in highly diluted, thrombin-activated plasma specimens. "
06/01/1999 - "The more potent antithrombotic effect of glycoprotein IIbIIIa antagonists may in addition be the result of reduced platelet factor Va expression and modulation of the platelet-dependent APC resistance phenotype."
10/01/1997 - "The physiological importance of this regulatory pathway is demonstrated by the occurrence of hereditary thrombophilia in individuals with a genetic defect that makes factor Va less sensitive to proteolytic inactivation by APC (APC resistance)."
08/01/2007 - "Further factor Va inactivation studies with the APC mutants revealed a similar role for the autolysis loop of APC in the interaction with its natural substrate."
07/01/2005 - "Moreover, a longer autolysis loop in APC is not optimal for interaction with factor Va in the absence of protein S, but it contributes to the lack of serpin reactivity and longer half-life of the protease in plasma."
07/15/2000 - "The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites."
08/29/1997 - "Additionally, autolysis loop-cleaved, active site-blocked native factor Xa was calculated to have approximately 10-fold reduced affinity for factor Va as compared with that of the noncleaved form."
06/01/2011 - "Activated protein C (APC) binds to its substrates activated factor V (FVa) and activated factor VIII (FVIIIa) with a basic exosite that consists of loops 37, 60, 70 and the autolysis loop. "
03/01/2005 - "The absence or dysfunction of factor Va leads to hemorrhagic diseases while prolonged existence of the active cofactor species is associated with thrombosis. "
01/01/1997 - "As a result, inactivation of factor-activated factor V by APC is impaired, which leads to a hypercoagulable state and a lifelong increased risk of thrombosis. "
05/01/2008 - "Arterial and venous thrombus formations were only slightly affected in mice carrying the factor V Leiden mutation, suggesting insensitivity to factor Va inactivation. "
05/01/2002 - "When factor Va is resistant to degradation by activated protein C, this anticoagulation pathway does not operate properly, and patients have an increased risk for thrombosis. "
01/01/1997 - "Factor V mutation at position 506 (replacement of an Arg by a Gln) results in a decrease of factor Va inactivation rate by APC and has been recently described as a thrombosis risk factor. "
|2.||Factor Xa (Coagulation Factor Xa)
|3.||Thromboplastin (Tissue Factor)
|4.||platelet factor V
|6.||Factor V (Coagulation Factor V)
|7.||factor V Leiden
|9.||Prothrombin (Factor II)